Study
| Phase I-II, open-label, multicenter study |
| Relapse or refractory large cell lymphoma |
| Glofitamab (n=132) |
Efficacy
| cORR: 56% [74 of 132 pts] |
| CR: 43% [ 56 of 132 pts] |
| mDoR: 18.4 mos [11.4-NR] |
Safety
| Grade≥3: CRS (4.3%), ICANS (4.8%) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf
Reviewed by Elvin CHALABİYEV, MD on AUG 10, 2023
